TMEM161A抗体—艾普蒂

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human liver cancer tissue using P08882(TMEM161A Antibody) at dilution 1/30. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human breast cancer tissue using P08882(TMEM161A Antibody) at dilution 1/30. (Original magnification: ×200)    

  
  

TMEM161A (Transmembrane Protein 161A) is a poorly characterized protein predicted to contain multiple transmembrane domains, suggesting a role in cellular membrane organization or transport. Its biological functions remain largely unexplored, though emerging studies link it to neurological disorders and cancer. For instance, TMEM161A expression alterations have been observed in glioblastoma and neurodevelopmental conditions, potentially implicating it in cell signaling or cytoskeletal regulation.

Antibodies targeting TMEM161A are primarily used as research tools to investigate its localization, expression patterns, and molecular interactions. These antibodies (polyclonal or monoclonal) are typically generated against specific epitopes, such as N-terminal or internal regions, and validated via Western blot, immunofluorescence, or immunohistochemistry in human or murine models. Commercial antibodies often cite applications in detecting TMEM161A in brain, kidney, or cancer tissues.

Current research focuses on clarifying TMEM161A's role in ion channel modulation, cell adhesion, or autophagy pathways. Challenges include its low expression levels and lack of definitive functional data. Reliable antibodies are critical for elucidating its contribution to diseases, though cross-reactivity risks with homologous proteins (e.g., TMEM161B) require careful validation. Ongoing studies aim to define its interactome and therapeutic potential in precision medicine contexts.